Phase 2 patient interviews identified mouth dryness as the most important symptom to improve in Sjögren's disease, while nipocalimab increased...

In a phase 3 trial, mavacamten reduced left ventricular outflow tract obstruction more than placebo in adolescents with symptomatic obstructive...

A phase II study reported high pathological response rates with perioperative ivonescimab, alone or with chemotherapy, for resectable NSCLC.

The FDA approved pirtobrutinib for previously untreated CLL/SLL without known 17p deletion after improved progression-free survival versus bendamustine plus rituximab.

The FDA lists potential safety risks for compounded peptide injections, including reported deaths associated with GHRP-2 and ipamorelin acetate.